Spectrum Pharmaceuticals, Inc. (SPPI): Price and Financial Metrics
GET POWR RATINGS... FREE!
SPPI Stock Price Chart Interactive Chart >
SPPI Price/Volume Stats
| Current price | $0.73 | 52-week high | $4.54 |
| Prev. close | $0.78 | 52-week low | $0.60 |
| Day low | $0.73 | Volume | 2,063,000 |
| Day high | $0.81 | Avg. volume | 3,882,906 |
| 50-day MA | $0.99 | Dividend yield | N/A |
| 200-day MA | $1.50 | Market Cap | 131.48M |
Spectrum Pharmaceuticals, Inc. (SPPI) Company Bio
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. The company was founded in 1987 and is based in Henderson, Nevada.
Latest SPPI News From Around the Web
Below are the latest news stories about Spectrum Pharmaceuticals Inc that investors may wish to consider to help them evaluate SPPI as an investment opportunity.
Spectrum Pharma announces resignation of CFOThe shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) are trading marginally lower in the pre-market on Wednesday after the commercial-stage biotech company announced the resignation of its Chief Financial Officer Kurt Gustafson. According to a regulatory filing, Mr. Gustafson has notified the company of his decision on Feb. 23, indicating his resignation... |
Spectrum Pharmaceuticals (SPPI) Receives a Buy from B.Riley FinancialB.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report) today and set a price target of $6.00. The company's shares closed last Friday at $0.72, close to its 52-week low of $0.60. According to TipRanks.com, Mamtani 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -18.7% and a 29.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Cognition Therapeutics. Currently, the analyst consensus on Spectrum Pharmaceuticals is a Strong Buy with an average price target of $6.67. |
Spectrum Pharmaceuticals Announces Acceptance of New Drug Application Filing for PoziotinibHENDERSON, Nev., February 11, 2022--Spectrum Pharmaceuticals Announces Acceptance of New Drug Application Filing for Poziotinib |
Down 55.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Spectrum Pharma (SPPI)The heavy selling pressure might have exhausted for Spectrum Pharma (SPPI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning, investor! |
SPPI Price Returns
| 1-mo | -20.37% |
| 3-mo | -1.12% |
| 6-mo | -58.99% |
| 1-year | -78.08% |
| 3-year | -90.52% |
| 5-year | -87.30% |
| YTD | -42.52% |
| 2021 | -62.76% |
| 2020 | -6.32% |
| 2019 | -58.40% |
| 2018 | -53.83% |
| 2017 | 327.77% |
Continue Researching SPPI
Want to do more research on Spectrum Pharmaceuticals Inc's stock and its price? Try the links below:Spectrum Pharmaceuticals Inc (SPPI) Stock Price | Nasdaq
Spectrum Pharmaceuticals Inc (SPPI) Stock Quote, History and News - Yahoo Finance
Spectrum Pharmaceuticals Inc (SPPI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...